Active Pharmaceutical Ingredients (APIs)

  • Indacaterol Maleate

    • API Product   :   

      Indacaterol Maleate

    • CEP   :   

      -

    • WCC   :   

      -

    • Therapeutic Use    :   

      Chronic Obstructive Pulmonary Disease(COPD)

    • Originator   :   

      Novartis

    • CAS No.    :   

      312753-06-3

    • Trade Name.   :   

      Onbrez, Arcapta

    • Molecular Weight   :   

      392.490 g/mol

    • Molecular Formula   :   

      C24H28N2O3

    Application

    Indacaterol is used to treat trouble breathing and wheezing due to a certain ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and/or emphysema). It is used if your breathing problems are not controlled with other medication (such as a quick-relief inhaler).

    General Description

    Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009,[2] and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011.[3] It needs to be taken only once a day,[4] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.